CYCN - Cyclerion Therapeutics Inc Stock Price, Fair Value and News

$1.530.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CYCN Price Action

Last 7 days

0.7%

Last 30 days

-17.7%

Last 90 days

-36.0%

Trailing 12 Months

-5.0%

CYCN RSI Chart

CYCN Valuation

Market Cap

6.0M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

2.1

Price/Free Cashflow

-4.37

CYCN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CYCN Fundamentals

CYCN Revenue

Revenue (TTM)

2.9M

Rev. Growth (Yr)

-76.51%

Rev. Growth (Qtr)

840.86%

CYCN Earnings

Earnings (TTM)

-2.2M

Earnings Growth (Yr)

-34.99%

Earnings Growth (Qtr)

-201.23%

CYCN Profitability

Return on Equity

-23.06%

Return on Assets

-21.11%

Free Cashflow Yield

-22.89%

CYCN Investor Care

Shares Dilution (1Y)

44.84%

Diluted EPS (TTM)

-0.74

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	1.6M	2.0M
2023	0	0	722.8K	1.1M
2022	4.6M	1.9M	1.6M	297.0K
2021	2.7M	3.1M	3.5M	3.9M
2020	4.0M	3.4M	2.8M	2.3M
2019	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Peter M. Hecht Ph.D.
WEBSITE	cyclerion.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	16

Cyclerion Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cyclerion Therapeutics Inc? What does CYCN stand for in stocks?

CYCN is the stock ticker symbol of Cyclerion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclerion Therapeutics Inc (CYCN)?

As of Wed Dec 03 2025, market cap of Cyclerion Therapeutics Inc is 6.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYCN stock?

You can check CYCN's fair value in chart for subscribers.

Is Cyclerion Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CYCN is over valued or under valued. Whether Cyclerion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cyclerion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCN.

What is Cyclerion Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, CYCN's PE ratio (Price to Earnings) is -2.73 and Price to Sales (PS) ratio is 2.1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCN PE ratio will change depending on the future growth rate expectations of investors.